Embecta Corp (EMBC)
Return on equity (ROE)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | 55,300 | 70,400 | -18,600 | 28,600 | 94,200 | 157,800 | |||
Total stockholders’ equity | US$ in thousands | -793,500 | -821,700 | -809,400 | -822,600 | -836,100 | -891,400 | -847,600 | -967,500 | 550,500 |
ROE | — | — | — | — | — | — |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $55,300K ÷ $-793,500K
= —
To analyze Embecta Corp's return on equity (ROE) based on the data provided, we need the net income and shareholders' equity figures for each period. Without this information, we are unable to calculate the ROE or provide a detailed analysis of its trend and performance over time. It is essential to have these financial figures to assess the company's profitability and how efficiently it is utilizing its equity to generate returns for shareholders. It is recommended to obtain the necessary financial data to conduct a comprehensive ROE analysis for Embecta Corp.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROE
Embecta Corp
EMBC
—
3M Company
MMM
-145.52%
Artivion Inc
AORT
-10.89%
Baxter International Inc
BAX
31.61%
Becton Dickinson and Company
BDX
4.96%
Boston Scientific Corp
BSX
8.25%
DexCom Inc
DXCM
26.18%
Glaukos Corp
GKOS
-29.16%
Globus Medical
GMED
3.07%
Haemonetics Corporation
HAE
12.25%
ICU Medical Inc
ICUI
-1.40%